This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
The Coronary Drug Project Research Group. 1973. The Coronary Drug Project: Design, methods, and baseline results. Circulation 47(Suppl I): I-1–I-79.
Organization, review and administration of cooperative studies (Greenberg Report): A report from the Heart Special Project Committee to the National Advisory Heart Council, May 1967. 1988. Control Clin Trials 9:137–148.
Canner PL. 1983. Monitoring of the data for evidence of adverse or beneficial effects. In, (Canner PL, ed.): The Coronary Drug Project. Methods and Lessons of a Multicenter Clinical Trial. Control Clin Trials 4:467–483.
FDA Draft Guidance on Data Monitoring Committees: http://www.fda.gov/OHRMS/DOCKETS/98fr/010489gd.pdf
NIH Policy for Data and Safety Monitoring: http://grants.nih.gov/grants/guide/noticefiles/not98-084.html
Ellenberg S, Fleming TR, DeMets DL. Data Monitoring Committees in Clinical Trials: A Practical Perspective. 2002. John Wiley & Sons, New York.
Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials, third edition. 1998. Springer-Verlag, New York.
Meinert CL. Clinical Trials: Design, Conduct and Analysis. 1986. Oxford University Press, New York.
Piantadosi S. Clinical Trials: A Methodologic Perspective. 1997. John Wiley & Sons, New York.
Pocock SJ. Clinical Trials: A Practical Approach. 1983, John Wiley & Sons, New York.
Freedman B. 1987. Equipoise and the ethics of clinical research. N Engl J Med 317:141–145.
The World Medical Association. World Medical Association Declaration of Helsinki: Ethical principals for medical research involving human subjects. October 2000 amended version, with 2002 clarification. http://www.wma.net/e/policy/b3.htm.
Canner PL. Monitoring clinical trial data for evidence of adverse or beneficial treatment effects. 1979. In Boissel JP, Klimt CR (eds.): Multicenter Controlled Trials: Principles and Problems. INSERM, Paris.
Rose EA, Moskowitz AJ, Packer M, Sollano JA,Williams DL,Tierney AR, Heitjan DF, Meier P, Ascheim DD, Levitan RG,Weinberg AD, Stevenson LW, Shapiro PA, Lazar RM,Watson JT, Goldstein DJ, Gelijns AC, for the REMATCH Investigators. 1999.The REMATCH trial: rationale, design, and end points. Ann Thorac Surg 67:723–730.
NIH Guidance on Reporting Adverse Events to Institutional Review Boards: http://grants.nih.gov/grants/guide/notice-files/not99-107.html
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
DeMets, D.L., Furberg, C.D., Friedman, L.M. (2006). Monitoring Committees: Why and How. In: DeMets, D.L., Furberg, C.D., Friedman, L.M. (eds) Data Monitoring in Clinical Trials. Springer, New York, NY. https://doi.org/10.1007/0-387-30107-0_1
Download citation
DOI: https://doi.org/10.1007/0-387-30107-0_1
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-20330-0
Online ISBN: 978-0-387-30107-5
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)